

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035860 A1**

- (51) International Patent Classification<sup>7</sup>: C12N 9/16, H. [US/US]; 81 Wooster Street, New York, NY 10032 (US).  
C07H 21/04
- (21) International Application Number: PCT/US02/34159 (74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).
- (22) International Filing Date: 24 October 2002 (24.10.2002) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/346,050 24 October 2001 (24.10.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 60/346,050 (CIP) Filed on 24 October 2001 (24.10.2001)
- (71) Applicant (*for all designated States except US*): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): BESTOR, Timothy,
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD FOR GENE IDENTIFICATION BASED ON DIFFERENTIAL DNA METHYLATION

(57) Abstract: This invention provides a method for detecting the presence of differential methylation between DNA from a first source and the corresponding DNA from a second source. Also provided is a method for determining the presence of a tumor suppressor gene in a DNA sample from a tumor cell.

**BEST AVAILABLE COPY**

A METHOD FOR GENE IDENTIFICATION BASED ON DIFFERENTIAL DNA METHYLATION

5 This application claims priority of provisional application U.S. Serial No. 60/346,050, filed October 24, 2001, the contents of which are incorporated herein by reference.

10 The invention described herein was made with government support under NIH Grant 1 R01-HG002425-01. Accordingly, the United States government has certain rights in this invention.

15 Throughout this application, various references are cited. Disclosure of these references in their entirety is hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

Background of the Invention

20 The mammalian genome contains approximately  $3 \times 10^7$  5-methylcytosine ( $m^5C$ ) residues, all or most at 5'- $m^5CpG$ -3'. About 60% of CpG sites are methylated in the DNA of somatic cells (Bestor et al., 1984; Li et al., 1992). Methylation recruits a variety of transcriptional repressors, including  
25 histone deacetylases and other proteins that cause chromosome condensation and silencing (Schübeler et al., 2000; reviewed by Bestor, 1998).

30 While it has long been known that methylation of a promoter causes profound silencing if the sequence is rich in CpG dinucleotides, only recently have genetic and biochemical experiments begun to identify the biological functions of DNA methylation after many years of controversy and speculation. It was only recently demonstrated that the large majority  
35 (>90%) of  $m^5C$  actually lies within intragenomic parasites such as transposons and endogenous retroviruses (which are rich in

-2-

the CpG dinucleotide and represent more than 45% of the genome; Smit, 1999), and it has been hypothesized that the primary function of cytosine methylation is host-defense against the transcription and dispersal of intragenomic parasites (Bestor, 1990; Bestor and Coxon, 1993; Bestor and Tycko, 1996; Yoder et al., 1997). Allele-specific cytosine methylation has been shown to be required for the monoallelic expression of some imprinted genes. When methylation levels are reduced as a result of homozygous targeted loss-of-function mutations in the *Dnmt1* gene, which encodes the major DNA methyltransferase of vertebrates (reviewed by Bestor, 2000), the imprinted genes *H19*, *Igf2*, and *Igf2r* are expressed at equal rates from both parental alleles (Li et al., 1993a; 1993b).

Demethylation of the *Xist* gene on the X chromosome activates *Xist* transcription and leads to inactivation of both X chromosomes in female cells and of the sole X in male cells (Panning and Jaenisch, 1996). Other data have shown that demethylation causes fulminating transcription of endogenous retroviral DNA to the point where retroviral transcripts become one of the predominant mRNA species of *Dnmt1* mutant embryos (Walsh et al., 1998). However, *Dnmt1* mutant embryos do not show ectopic or precocious activation of tissue specific genes, and in fact the promoters of such genes are not normally methylated in non-expressing tissues (Walsh and Bestor, 1999). This suggested that DNA methylation might have primary roles in processes other than reversible gene regulation during development.

There has been much controversy over the biological roles of cytosine methylation. The biological importance of cytosine methylation was long in doubt, in large part because the DNA of familiar laboratory organisms (notably yeast, *Drosophila*, and *C. elegans*) lack modified bases. However, genetic studies in mice and humans have shown that abnormalities of genomic

-3-

methylation patterns have severe phenotypic consequences. Disruption of the *Dnmt1* gene (Bestor et al., 1988) showed that demethylation of the genome caused apoptotic cell death in all differentiating cell types, fulminating expression of normally  
5 silenced retroposons, loss of imprinted expression at a number of imprinted loci, ectopic X inactivation, and marked chromosome instability manifested as a high rate of deletions and rearrangements (reviewed by Bestor, 2000).

10 Human genetic disorders were recently shown to be caused by mutations in a DNA methyltransferase gene (Xu et al., 1999) and in a gene that encodes a protein that binds to methylated DNA (Amir et al., 1999). The first of these, ICF syndrome, is characterized by immunodeficiency, centromere instability, and  
15 facial anomalies. The cytogenetic abnormalities are extreme; chromosomes 1, 9, and 16 gain and lose short arms such that a single chromosome can have as many as 12 short arms. The resulting pinwheel chromosomes are highly diagnostic. The breakage and rejoining occurs at tracts of classical satellite  
20 DNA, which is normally heavily methylated but is completely unmethylated in DNA of ICF patients. It has been shown that ICF syndrome is due to inactivating point mutations in the DNMT3B gene on chromosome 20 (Xu et al., 1999).

25 The second syndrome, Rett syndrome, is a common neurodevelopmental syndrome in which normal early development is followed by a regression in all neural functions leading to complete apraxia and death by aspiration pneumonia or heart failure. The syndrome is due to mutations in *MeCP2*, which  
30 encodes a transcriptional repressor that binds specifically to methylated DNA (Amir et al., 1999).

Methylation abnormalities have also been seen in patients suffering from ATRX (alpha thalassemia and mental retardation  
35 on the X) syndrome (Gibbons et al., 2000). The genetic findings

-4-

in both mice and humans confirm that cytosine methylation has multiple essential roles. There is, however, much remaining uncertainty and continuing controversy as to the nature of those roles.

5

Another aspect of genomic methylation patterns is the frequent finding of ectopic *de novo* methylation of CpG islands associated with tumor suppressor genes in human tumors and tumor cells lines (reviewed by Warnecke and Bestor, 2000).

10

First observed at RB1, ectopic promoter methylation has come to be regarded as a common mechanism by which tumor suppressor genes are inactivated in cancer. However, there is little direct evidence that the observed methylation is responsible for the silencing, and most studies have used DNA from cultured

15

tumor cell lines in which genomic methylation patterns are very unstable. Nonetheless, the high frequency with which promoter methylation is observed at tumor suppressor loci indicates the possibility that this feature can be used to identify candidate tumor suppressor genes that might not be identified through

20

other means.

Given that inherited and somatic changes in methylation patterns are involved in human disease, it is unfortunate that so little should be known of the basic organization of genomic

25

methylation patterns. The methylation landscape of the human genome, as well as the role of methylation pattern dynamics in normal development, carcinogenesis, and human genetic disorders remains an important area for exploration. Unfortunately, there remains a need for experimental methods suitable for

30

investigating methylation's role in the genome.

-5-

Summary of the Invention

This invention provides a method for detecting the presence of differential methylation between DNA from a first source and the corresponding DNA from a second source, which method  
5 comprises the steps of

(a) (i) contacting an agent that degrades methylated DNA with a DNA sample from the first source, under suitable  
10 conditions, so as to degrade methylated DNA in the first sample, and (ii) contacting an agent that degrades unmethylated DNA with a DNA sample from the second source, under suitable conditions, so as to degrade unmethylated DNA in the second sample;

15 (b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the first source and a DNA strand from the second source, should  
20 both such strands be present; and

(c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of  
25 differential methylation between the DNA from the first source and the corresponding DNA from the second source.

This invention also provides a method for determining the presence of a tumor suppressor gene in a DNA sample from a  
30 tumor cell, which method comprises the steps of

(a) (i) contacting an agent that degrades unmethylated DNA with the DNA sample from the tumor cell, under  
suitable conditions, so as to degrade unmethylated DNA in  
35 the sample, and (ii) contacting an agent that degrades

-6-

methyated DNA with a DNA sample from a normal cell corresponding to the tumor cell, under suitable conditions, so as to degrade methyated DNA in the sample;

5

(b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the normal cell and a DNA strand from the tumor cell, should both such strands be present;

10

(c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of differential methylation between the DNA from the normal cell and the corresponding DNA from the tumor cell; and

15

(d) determining whether the DNA strand from the tumor cell in the hybrid DNA duplex detected in step (c) comprises a tumor suppressor gene, thereby determining the presence of a tumor suppressor gene in the DNA sample from the tumor cell.

20

-7-

Brief Description of the FiguresFigure 1

Organization of transposons, exons, and HpaII (CCGG) sites within the human HPRT gene. Organization of HPRT is typical of human genes (Yoder et al., 1997). CCGG sites located in known transposons and in cellular sequences are shown in contrasting shades; note the concentration of cellular CCGG sites in the CpG island at the 5' end of the gene. Nearly all of the CCGG sites within the body of the gene are in transposons. As shown by the scale at right the gene is methylated at these sites and unmethylated at the CpG island, as is true of the large majority of cellular genes. The CpG island undergoes dense *de novo* methylation when located on the inactive X chromosome, but is completely unmethylated on the active X (Litt et al., 1996). CCGG sites are shown here as they are most often used to evaluate methylation patterns by Southern blot analysis.

Figures 2A-2C

Removal of methylated sequences by McrBC digestion and of unmethylated sequences by RE digestion. (2A) Unmethylated *S. pombe* DNA was resistant to McrBC digestion (lane 3); after methylation of all CpG sites by treatment with M.SssI it became very sensitive (lane 4). Unmethylated *S. pombe* DNA is very sensitive to RE treatment (lane 5; discrete bands were derived from very G + C-poor mitochondrial DNA). (2B) McrBC-resistant fragments in human Jurkat test DNA (lane 2) were sensitive to RE treatment, indicating that they were in fact unmethylated in the starting DNA and did contain CpG sites. (2C) Methylation of human DNA at all CpG sites with M.SssI shows that the McrBC-resistant fraction > 500 bp in lane 5 is unmethylated, as shown by the acquisition of McrBC sensitivity after M. SssI treatment (lane 3). Gap below 500 bp in all panels is artifact of bromphenol blue.



-8-

Figure 3

Removal of endogenous methylated sequences from McrBC libraries. LINE-1 (L1) elements (left) and satellite 3 DNA are normally heavily methylated. The figure shows that these  
5 sequences are largely removed from human DNA by digestion with McrBC. The size range is set between the lower limit for CpG islands (~500 bp) and the upper limit for clonability in plasmid vectors.

## Detailed Description of the Invention

### Definitions

5 As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.

10 "Normal cell corresponding to a tumor cell" shall mean a non-diseased cell of the same type as that from which the tumor cell originated.

15 "Source of DNA" includes, but is not limited to, a normal tissue, a diseased tissue, a cell, a virus, and populations thereof, a biological fluid sample, a cultured cell or population thereof, a tissue or cell biopsy, a pathological sample, a forensic sample, a chromosome, chromatin, genomic DNA, a DNA library and an isolated gene.

20 As used herein, "subject" means any animal or artificially modified animal. Animals include, but are not limited to, mice, rats, dogs, guinea pigs, ferrets, rabbits, and primates. In the preferred embodiment, the subject is a human.

### 25 Embodiments of the Invention

This invention provides a first method for detecting the presence of differential methylation between DNA from a first source and the corresponding DNA from a second source, which  
30 method comprises the steps of

35 (a) (i) contacting an agent that degrades methylated DNA with a DNA sample from the first source, under suitable conditions, so as to degrade methylated DNA in the first sample, and (ii) contacting an agent that degrades

-10-

unmethylated DNA with a DNA sample from the second source, under suitable conditions, so as to degrade unmethylated DNA in the second sample;

5 (b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the first source and a DNA strand from the second source, should  
10 both such strands be present; and

(c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of differential methylation between the DNA from the first  
15 source and the corresponding DNA from the second source.

In one embodiment, the first method further comprises the step of modifying the DNA of parts (i) and (ii) resulting from step (a) with a first and second moiety, respectively, so as to  
20 prevent, in step (b), the formation of a DNA duplex consisting of DNA strands from the first source or of a DNA duplex consisting of DNA strands from the second source. In one example, the modification of at least one sample resulting from step (c) comprises modifying the DNA in at least one  
25 sample with a moiety which facilitates the isolation of hybrid DNA duplexes formed in step (b). Such moieties are well known in the art and include, for example, biotin.

In another embodiment, the first method further comprises the  
30 step of determining the nucleic acid sequence of a hybrid DNA duplex whose presence is detected in step (c). In one example, this step further comprises the step of identifying the methylated nucleotide residues of one or both strands of the hybrid DNA duplex whose sequence is determined.

35

-11-

In the first method, the first and second sources of DNA can be any suitable sources such as, for example, (i) a cell from a first tissue of a subject and a cell from a second tissue of that subject, respectively; (ii) a cell from a normal tissue and a cell from that tissue in a diseased state, respectively;  
5 (iii) chromosomes of a chromosome pair; (iv) a DNA library; and (v) an isolated gene. In the preferred embodiment, the isolated gene is a tumor suppressor gene.

10 In another embodiment of the first method, the agent that degrades methylated DNA is McrBC. In another embodiment, the agent that degrades unmethylated DNA comprises a methylation-sensitive restriction endonuclease. In one embodiment, the methylation-sensitive restriction endonuclease is selected  
15 from the group consisting of HpaII, HhaI, MaeII, BstUI and AciI. In a further embodiment, the agent that degrades unmethylated DNA comprises a plurality of methylation-sensitive restriction endonucleases. Preferably, the plurality of methylation-sensitive restriction endonucleases  
20 is selected from the group consisting of HpaII, HhaI, MaeII, BstUI and AciI.

In the preferred embodiment, the DNA from the first and second sources is human DNA.

25

This invention also provides a second method for determining the presence of a tumor suppressor gene in a DNA sample from a tumor cell, which method comprises the steps of

30 (a) (i) contacting an agent that degrades unmethylated DNA with the DNA sample from the tumor cell, under suitable conditions, so as to degrade unmethylated DNA in the sample, and (ii) contacting an agent that degrades methylated DNA with a DNA sample from a normal cell  
35 corresponding to the tumor cell, under suitable

-12-

conditions, so as to degrade methylated DNA in the sample;

5 (b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the normal cell and a DNA strand from the tumor cell, should both such strands be present;

10 (c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of differential methylation between the DNA from the normal cell and the corresponding DNA from the tumor cell; and

15 (d) determining whether the DNA strand from the tumor cell in the hybrid DNA duplex detected in step (c) comprises a tumor suppressor gene, thereby determining the presence of a tumor suppressor gene in the DNA sample  
20 from the tumor cell.

The various embodiments set forth above with respect to the first method of this invention apply *mutatis mutandis* to the second method of this invention.

25 This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as  
30 described more fully in the claims which follow thereafter.

-13-

Experimental DetailsBackground5           *Host Defense Hypothesis*

Applicants were the first to purify, characterize, and clone a eukaryotic DNA methyltransferase (Dnmt1; Bestor et al., 1988). Applicants also disrupted the *Dnmt1* gene (in  
10 collaboration with R. Jaenisch) and demonstrated that cytosine methylation is essential for mammalian development (Li et al., 1992). Several of the biological functions of cytosine methylation have been deduced from studies of *Dnmt1* mutant mice. The *Dnmt1* gene was the first gene shown to have sex-  
15 specific promoters and first exons (Mertineit et al., 1998), and deletion of the female-specific promoter and first exon was the first pure maternal-effect mutation to be observed in a mammal (Howell et al., 2001). Applicants also found the first human genetic disorder to be caused by mutations in a  
20 DNA methyltransferase gene (Xu et al., 1999), and were the first to solve the crystal structure of a eukaryotic DNA methyltransferase homologue, human DNMT2 (Dong et al., 2001), whose function is unknown and is currently under study.

25 Applicants also put forward the idea that the primary function of cytosine methylation is likely to be host defense against transposons (Bestor, 1990; Yoder et al., 1997; Bestor, 2000). The host defense hypothesis has come to be supported by a large body of evidence and has received increasingly positive  
30 regard after a somewhat emotional reception by colleagues devoted to the developmental hypothesis. However, until more is known of the large-scale patterning of cytosine methylation in the genome, there will be continuing controversy as to the biological functions of methylation patterns.

35

-14-

*The shape of genomic methylation patterns*

Cytosine methylation is erased by cloning in microorganisms or by PCR amplification and information on methylation patterns is therefore absent from the human genome sequences produced by both the public and private sequencing efforts.

Current methods for the analysis of cytosine methylation are ineffective. These methods involve Southern blot analysis after cleavage with methylation-sensitive restriction endonucleases or PCR across the restriction sites of such enzymes, or the sequencing of genomic DNA after deamination by sodium bisulfite treatment, which converts all cytosines to uracils but does not convert  $m^5C$  so that all remaining cytosines must have been derived from  $m^5C$ .

These traditional methods have inherent limitations appropriate to their pre-genomics beginnings; they are very limited in scope and can be used to test only small regions; they require that the sequences be known in advance and cannot be used to extract sequences that are heavily methylated or largely unmethylated, and the Southern blot method (which is most widely used) can examine only a few sites with narrow spacing requirements. It is the CpG density and methylation status of regions of hundreds of base pairs, rather than single CpG sites, that appear to control promoter activity (Kass et al., 1997). Examination of single sites, which are usually chosen on the basis of convenience, can therefore be quite misleading. In addition to these technical issues, it is common to work with DNA from established lines of cultured cells rather than tissue DNA. Genomic methylation patterns are highly unstable in cultured cells, and in cell lines the promoters of tissue-specific genes are frequently methylated at positions that are not methylated in non-expressing tissues. The muscle-specific  $\alpha$ -actin gene, for example, is

-15-

methyated in most mouse and human cell lines but is not methyated in mouse brain, liver, or spleen, tissues that do not express  $\alpha$ -actin (Walsh and Bestor, 1999).

5 Although the extant data are fragmentary and often contradictory, a few themes do emerge repeatedly. First, promoter regions that are heavily methyated in tissues are normally silent (examples are imprinted genes and those on the inactive X chromosome in females, and promoters that have  
10 undergone *de novo* methylation in cultured cells or tumors). Second, CpG islands (regions of high G + C content and CpG density which span or overlap the 5' ends of most genes) are unmethyated in the germ line and in all somatic tissues, except when associated with imprinted genes or those subject  
15 to X inactivation. Third, gene silencing usually involves methylation of all or nearly all CpG sites in CpG islands that are 500-2,000 base pairs in length; methylation of non-CpG island sequences does not usually prevent transcription (Kass et al., 1997), and the binding of transcription factors can  
20 actually cause demethylation of local CpG sites (Lin et al., 2000). Fourth, the large majority of genomic m<sup>5</sup>C is within transposons, which are abundant (45% of the mammalian genome; Smit, 1999) and relatively rich in CpG dinucleotides. More than 90% of genomic m<sup>5</sup>C lies with retrotransposons (Yoder et al.,  
25 1997), and other repeated sequences such as pericentric satellite DNA account for much of the remainder. However, it must be kept in mind that the regulatory regions of cellular genes represent much less than 1% of the total genome, and this small contribution will not be detectable against the  
30 large background of heavily methyated transposons and other repeated sequences.

Most genes have unmethyated promoters in both expressing and non-expressing tissues, although the transcribed regions tend  
35 to be methyated. That is because introns are rich in



-16-

transposons, which are largely methylated. This is illustrated by examination of the *HPRT* gene in Figure 1. The genome browser (<http://genome.ucsc.edu/goldenPath/septTracks.html>; please note that all references to "genome browser" refer to this software) annotates transposon distributions, and all long genes can be seen to contain multiple transposons. Some, such as *VHL*, are more than 50% transposon.

While the above suggests that the genome is characterized by unmethylated single copy cellular sequences embedded in a background of methylated transposons, the situation is actually more complex. CpG sites in exons can be heavily methylated if they lie close to transposons in flanking introns. Such CpG sites are especially vulnerable to C → T transition mutations driven by deamination of m<sup>5</sup>C (Magewu and Jones, 1994). CpG islands can be heavily methylated in normal cells, as in the case of imprinted genes and those subject to X inactivation, and much demethylation (Feinberg and Vogelstein, 1983) and *de novo* methylation is seen in DNA of cancer cells (reviewed by Warnecke and Bestor, 2000). Stochastic and ectopic *de novo* methylation has been attributed a role in human disorders in which there appear to be both genetic and epigenetic contributions to phenotype (Petronis et al., 2000). However, once again the lack of knowledge of the large-scale patterning of m<sup>5</sup>C in the genome, and the lack of a known method for the extraction of differentially methylated sequences, has engendered controversy and slowed progress.

### Methods and Results

Applicants have developed methods for the selective cloning of the heavily methylated compartment and the unmethylated compartment of the genome. The methylated compartment is resistant to methylation-sensitive restriction endonucleases.

-17-

Applicants use a mixture of 5 such enzymes (HpaII, C\*CGG; MaeII, A\*CGT; BstUI, \*CG\*CG, HhaI, G\*CGC, and AciI, CC\*GC and G\*CGG; asterisk identifies site of methylation that prevents cleavage). The unmethylated compartment is resistant to

5 McrBC, an *E. coli* enzyme complex that binds to sequences of the form  $Rm^5C-(N)_{40-500}-Rm^5C$  and degrades all internal sequences to small fragments (Stewart and Raleigh, 1998). Little degradation is seen when the two half-sites are more than 500 base pairs apart. The unmethylated sequences in most CpG

10 islands are greater than 500 base pairs (Cross et al., 2000). The genome browser flags CpG islands of <400 base pairs as questionable based on length alone.

To confirm the reported behavior of the enzymes, applicants

15 first treated the unmethylated DNA of *Schizosaccharomyces pombe* with McrBC (New England Biolabs) or with the mixture of methylation-sensitive restriction endonucleases (referred to as "RE treatment"). As shown in Figures 2A-2C, the unmethylated DNA was completely resistant to McrBC, but was

20 degraded to small fragments by RE treatment (lanes 3 and 5; bands in lane 5 are from mitochondrial DNA, which is A + T-rich and poor in CpG dinucleotides). When *S. pombe* DNA was methylated at all CpG sites by *in vitro* treatment with the DNA methyltransferase M.SssI (New England Biolabs) and S-AdoMet,

25 it was rendered completely resistant to RE (lane 6) treatment but became very sensitive to McrBC (lane 4). The DNA of cultured Jurkat cells (a human T cell leukemia cell line) was sensitive to McrBC, but markedly less so than artificially methylated *S. pombe* DNA, which has no unmethylated compartment

30 (lanes 4 and 8). These test data confirm that McrBC and RE treatment have the expected effects on methylated and unmethylated sequences.

Even though McrBC has relaxed sequence and spacing

35 requirements, it was of concern that the McrBC-resistant

-18-

fraction shown above may have been derived from methylated DNA that has a very low CpG density and therefore lacks half sites in the configuration required for McrBC digestion. If this were so, the McrBC-resistant fraction would also be RE resistant as a result of methylation or sparse CpG sites. As shown in Figure 2B, the McrBC-resistant fraction is very sensitive to RE treatment, and Figure 2C shows that methylation of CpG sites converts the McrBC resistant fraction to McrBC-sensitive. These data confirm that the McrBC library is composed largely of unmethylated CpG-containing sequence tracts.

Applicants next confirmed that sequence compartments in the human genome that are known to be heavily methylated can be eliminated by McrBC digestion but resist RE treatment. Applicants chose the promoter region of a LINE-1 element, L1.3, that has been shown to belong to a family of actively transposing L1 elements (reviewed by Kazazian and Moran, 1998). These have been found to be heavily methylated in all cell types examined. Also tested was classical satellite 3 DNA from chromosome 9, which is densely methylated in all normal cells but is unmethylated in patients with ICF syndrome and in certain tumor types (Xu et al., 1999). As shown in Figure 3, the specific methylated sequences could be almost completely removed by McrBC treatment. Applicants have prepared plasmid libraries of human genomic DNA restricted by McrBC or by RE treatment. A size selection is performed as indicated in Figure 3 to reduce the already low background, and the DNA is cloned into the SmaI site of pBluescript after blunting insert ends with T4 DNA polymerase. These McrBC libraries will be depleted in heavily methylated sequences, while the RE libraries will be enriched in such sequences.

These data show that the instant methods allow the selective cloning of both the unmethylated and heavily methylated

-19-

compartments of the genome. Sequence analysis of McrBC and RE libraries permits the first objective large-scale view of the methylation landscape of the human genome. These data also facilitate the identification of CpG islands by objective  
5 criteria. The present computational methods must use arbitrary thresholds for CpG density and G + C content and tend to overestimate CpG island number by a factor of 2. For example, distal 21q contains 110 genes, but 234 predicted CpG islands. It seems unlikely that gene number was  
10 underestimated by a factor of 2. Subtractive hybridization of the McrBC and RE libraries permits selective extraction of sequences that are differentially methylated between normal and cancer cells, between tissues of normal individuals and those with genetic disorders such as Rett and ICF syndromes,  
15 and between alleles in the case of imprinted genes. All these data can be analyzed on-line by new computational methods and added as annotation to the human genome browser in a fully automated and almost real-time basis.

## 20 Discussion

In the mammalian genome, DNA methylation occurs predominantly at cytosine residues found in the context of CpG dinucleotides. In contrast to genetic alterations, cytosine  
25 methylation is an epigenetic modification, which is potentially reversible and does not alter DNA sequence. As the most well characterized mechanism of epigenetic regulation, DNA methylation has been implicated in a number of biological processes, including genomic imprinting, X-  
30 inactivation, and silencing of parasitic DNA. Abnormal cytosine methylation is thought to contribute to disease states, as aberrant genomic methylation patterns have been observed in cancer and genetic disorders, such as ICF Syndrome and Rett Syndrome, as well as schizophrenia. Demethylation  
35 also destabilizes the genome and can contribute to the

-20-

development of cancer. Given the deleterious effects of aberrant DNA methylation, it is surprising how little is known about normal methylation patterns in the mammalian genome. This is due in part to the lack of efficient methods for the  
5 identification of regions of the genome that differ in methylation status between cell types. Such a method would be very powerful in the identification of tumor suppressors; once identified, such new tumor suppressors become targets of rational drug design.

10

Until recently, the analysis of altered methylation patterns has been limited to a small number of predetermined genes. Traditional molecular biology techniques, such as Southern blotting and polymerase chain reaction (PCR), are not capable  
15 of analyzing global methylation patterns and they cannot be used to isolate sequences on the basis of abnormal methylation status. The more recent use of Restriction Landmark Genome Scanning (RLGS) and Methylation-Sensitive Representational Difference Analysis (MS-RDA) have met with limited success.  
20 RLGS is a cumbersome, labor-intensive method in which methylation changes are visualized as a dense cluster of "spots" on 2-dimensional gels. This poor resolution presents major difficulties in the identification and isolation of genomic loci, making it unsuitable for high-throughput. MS-  
25 RDA is a PCR-based technique that is biased toward short DNA fragments and against GC-rich sequences. Novel array-based methods have also been developed, but these rely heavily on hybridization kinetics. All existing methods are vulnerable to the presence of normal cells in the diseased tissue. With  
30 the increasing emphasis on the potential role of methylation in human diseases, there is an immediate need for an effective method for identifying genome-wide changes in DNA methylation in human tissue samples.

35 To meet this need, applicants have developed a novel method

-21-

for identifying alterations in DNA methylation. This procedure, which applicants refer to as Methylation Subtraction Analysis (MSA), relies on the enzymatic fractionation of the human genome into its methylated and unmethylated compartments. This fractionation method coupled with standard molecular biology techniques facilitates the identification and isolation of genomic sequences that are unmethylated in normal tissue but have become hypermethylated in disease tissue.

MSA offers several key advantages over other techniques for identifying global changes in DNA methylation. Most importantly, genomic DNA used in this procedure can be obtained directly from normal and disease tissues rather than cultured cell lines. This point is underscored by the recent observation that more than 57% of sequences found to be methylated in cultured tumor cells were not methylated in the corresponding primary tumors. In some tumors, the error rate is 97% (Smiraglia et al., 2001). Another advantage of MSA is that it is insensitive to contamination of tumor samples by normal cells. One of the difficulties in analyzing tumor samples, for instance, is that the tumors themselves are often a heterogeneous mix of wild-type and cancerous cells. MSA has been designed so that methylated sequences from disease cells will be enzymatically removed from unmethylated genomic libraries derived from normal tissue while unmethylated sequences will be enzymatically removed from methylated libraries derived from disease tissue. This allows for accurate identification of genomic loci that display differential methylation between the normal and disease tissues. Finally, the robust and streamlined nature of the MSA procedure makes it ideal for high-throughput analyses of genome-wide methylation differences. Since the final readout is actual DNA sequence, MSA avoids the tedious cloning of individual candidate loci, which is a major obstacle to high-

-22-

throughput analysis.

From a commercialization standpoint, the MSA procedure has several research and clinical applications. Several tumor-suppressor genes have been identified based on the observation that they are aberrantly methylated in cancerous cells. This number, however, is an underestimation, primarily due to the limitations of existing methods for analyzing genome-wide methylation changes. To this end, MSA is well suited for the identification of new tumor-suppressor genes as well genes that may contribute to other human disorders. Newly identified genes may serve as targets for future therapies that focus on targeted demethylation. By a simple modification of the fractionation procedure, MSA can also detect the loss of methylation. This can be used to identify new oncogenes that are normally silenced by methylation but have become activated during the oncogenic process. The proteins encoded by these genes may be potential drug targets that drive the development of new treatments.

20

While methylation status of a genomic locus does not always signify its involvement in a particular disease, the methylation patterns themselves undoubtedly have diagnostic and prognostic value in the treatment of disease. For example, certain tumor types may have different hypermethylation profiles during the course of tumor progression. These tumor-specific profiles can facilitate early cancer diagnosis as well as cancer prognosis. MSA is well suited for the large-scale extraction of sequences subject to aberrant methylation in human cancer. Methylation analysis is an entirely new route to the identification of tumor suppressors.

30

-23-

References

- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.* 23, 185-188.
- Antequera F, Bird A (1993) Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci USA* 90, 11995-11999.
- Bestor TH (1990) DNA methylation: How a bacterial immune function has evolved into a regulator of gene expression and genome structure in higher eukaryotes. *Phil. Trans. Royal Soc. Lond. B* 326, 179-187.
- Bestor TH (1998) Gene silencing. Methylation meets acetylation. *Nature* 393, 311-312.
- Bestor TH (2000) The DNA methyltransferases of mammals. *Hum. Mol. Gen.* 9, 2395-2402.
- Bestor TH (2000A) Sex brings transposons and genomes into conflict. *Genetica* 207, 289-295.
- Bestor TH (2000B) Gene silencing as a threat to the success of gene therapy. *J. Clin. Invest.* 105, 409-411.
- Bestor TH, Coxon A (1993) The pros and cons of DNA methylation. *Curr. Biol.* 3, 384-386.
- Bestor TH, Hellewell SB, Ingram VM (1984) Differentiation of two mouse cell lines is associated with hypomethylation of their genomes. *Mol Cell Biol.* 4, 1800-1806.



-24-

Bestor TH, Laudano A, Mattaliano R, and Ingram V (1988)  
Cloning and sequencing of a cDNA encoding DNA  
methyltransferase of mouse cells. The carboxyl-terminal  
domain of the mammalian enzyme is related to bacterial  
5 restriction methyltransferases. *J. Mol. Biol.* 203, 971-983.

Bestor TH, and Tycko B (1996) Creation of genomic methylation  
patterns. *Nature Genetics* 12, 363-367.

10 Caspary T, Cleary MA, Baker CC, Guan XJ, Tilghman SM (1998)  
Multiple mechanisms regulate imprinting of the mouse distal  
chromosome 7 gene cluster. *Mol Cell Biol.* 18, 3466-74.

Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP,  
15 Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller  
DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R,  
Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA,  
Cavenee WK, Plass C (2000) Aberrant CpG-island methylation  
has non-random and tumour-type-specific patterns. *Nat Genet.*  
20 24, 132-138.

Cross SH, Clark VH, Simmen MW, Bickmore WA, Maroon H, Langford  
CF, Carter NP, Bird AP (2000) CpG island libraries from human  
chromosomes 18 and 22: landmarks for novel genes. *Mamm Genome*  
25 11, 373-383.

Dong A, Yoder JA, Zhou L, Xing Z, Bestor TH, and Cheng X  
(2001) Structure of Human DNMT2, an enigmatic DNA  
methyltransferase homologue that displays denaturant-resistant  
30 binding to DNA. *Nucl. Acids Res.* 29, 439-448.

Feinberg AP and Vogelstein B (1983) Hypomethylation  
distinguishes genes of some human cancers from their normal  
counterparts. *Nature* 301, 89-92.

35

-25-

Gibbons RJ, McDowell TL, Raman S, O'Rourke DM, Garrick D, Ayyub H, Higgs DR (2000) Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. *Nat Genet.* 24, 368-371.

5

Howell, CY, Bestor, TH, Deng, F, Latham, KE, Mertineit, C, Trasler, JM, and Chaillet, JR (2001) Genomic imprinting disrupted by a maternal effect mutation in the mouse *Dnmt1* gene. *Cell* 104, 829-838.

10

Jaakkola T, Diekhans M, Haussler D (2000) A discriminative framework for detecting remote protein homologies. *J Comput Biol.* 7, 95-114.

15 Kass SU, Landsberger N, Wolffe AP (1997) DNA methylation directs a time-dependent repression of transcription initiation. *Curr Biol.* 7, 157-165.

Kazazian HH Jr, Moran JV (1998) The impact of L1 retrotransposons on the human genome. *Nat Genet.* 19, 19-24.

20

Kuromitsu J, Yamashita H, Kataoka H, Takahara T, Muramatsu M, Sekine T, Okamoto N, Furuichi Y, Hayashizaki Y (1997) A unique downregulation of h2-calponin gene expression in Down syndrome: a possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21. *Mol Cell Biol* 17, 707-712.

25

Li E, Beard C, Forster AC, Bestor TH, Jaenisch R (1993A) DNA methylation, genomic imprinting, and mammalian development. *Cold Spring Harb Symp Quant Biol* 58, 297-305.

30

Li E, Beard C, Jaenisch R (1993b) Role for DNA methylation in genomic imprinting. *Nature* 366, 362-365.

-26-

Li E, Bestor TH, and Jaenisch R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 69, 915-926.

5 Lin IG, Tomzynski TJ, Ou Q, Hsieh CL (2000) Modulation of DNA binding protein affinity directly affects target site demethylation. *Mol Cell Biol* 20, 2343-2349.

10 Lisitsyn N, Lisitsyn N, Wigler M. (1993) Cloning the differences between two complex genomes. *Science* 259, 946-951.

Litt MD, Hornstra IK, Yang TP (1996) *In vivo* footprinting and high-resolution methylation analysis of the mouse hypoxanthine phosphoribosyltransferase gene 5' region on the active and  
15 inactive X chromosomes. *Mol Cell Biol* 16, 6190-9619.

Magewu AN, Jones PA (1994) Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in  
20 human cancer. *Mol Cell Biol* 14, 4225-4232.

Mertineit C, Yoder JA, Takedo T, Laird D, Trasler J, and Bestor TH (1998) Sex-specific exons control DNA methyltransferase in mammalian germ cells. *Development* 125,  
25 889-897.

Panning B, Jaenisch R (1996) DNA hypomethylation can activate Xist expression and silence X-linked genes. *Genes Dev.* 10, 1991-2002.

30

Petronis A, Gottesman II, Crow TJ, DeLisi LE, Klar AJ, Macciardi F, McInnis MG, McMahon FJ, Paterson AD, Skuse D, Sutherland GR (2000) Psychiatric epigenetics: a new focus for the new century. *Mol Psychiatry.* 5, 342-346.

35

-27-

Piras G, El Kharroubi A, Kozlov S, Escalante-Alcalde D, Hernandez L, Copeland NG, Gilbert DJ, Jenkins NA, Stewart CL (2000) *Zac1* (*Lot1*), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. *Mol Cell Biol.* 20, 3308-3315.

Schübeler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, Bouhassira EE, Groudine M (2000) Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. *Mol Cell Biol* 20, 9103-9112.

Shibata H, et al. (1994) Genetic mapping and systematic screening of mouse endogenously imprinted loci detected with restriction landmark genome scanning method (RLGS). *Mamm Genome* 5, 797-800.

Smit AF (1999) Interspersed repeats and other mementos of transposable elements in mammalian genomes. *Curr Opin Genet Dev.* 9, 657-663.

Stewart, FJ, Raleigh, EA (1998) Dependence of *McrBC* cleavage on distance between recognition elements. *Biol Chem* 379, 611-616.

Turker MS, Swisshelm K, Smith AC, Martin GM (1989) A partial methylation profile for a CpG site is stably maintained in mammalian tissues and cultured cell lines. *J Biol Chem* 264, 11632-11636.

Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T, Nagao M (1997) Establishment of methylation-sensitive-representational difference analysis and isolation

-28-

of hypo- and hypermethylated genomic fragments in mouse liver tumors. *Proc Natl Acad Sci USA* 94, 2284-2289.

Warnecke PM and Bestor TH (2000) Cytosine methylation and  
5 human neoplasia. *Curr Op Oncology* 12, 68-73.

Walsh CP, Bestor TH (1999) Cytosine methylation and mammalian development. *Genes & Devel.* 13, 26-34.

10 Walsh CP, Chaillet JR, Bestor, TH (1998) Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. *Nature Genetics* 20, 116-117.

Xu G-L, Bestor TH, Bourc'his D, Hsieh C-L, Tommerup N, Bugge  
15 G, Hulten M, Qu X, Russo JJ, Viegas-P'equignot E (1999) Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* 402, 187-191.

20 Yoder JA, and Bestor TH (1998) A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. *Hum. Mol. Gen.* 7, 279-284.

Yoder JA, Walsh CP, and Bestor TH (1997) Cytosine methylation  
25 and the ecology of intragenomic parasites. *Trends Genet.* 13, 335-340.

Zhu X, Deng C, Kuick R, Yung R, Lamb B, Neel JV, Richardson B, Hanash S (1999) Analysis of human peripheral blood T cells and  
30 single-cell-derived T cell clones uncovers extensive clonal CpG island methylation heterogeneity throughout the genome. *Proc Natl Acad Sci* 96, 8058-8063.

-29-

What is claimed is:

1. A method for detecting the presence of differential methylation between DNA from a first source and the corresponding DNA from a second source, which method comprises the steps of:
  - (a) (i) contacting an agent that degrades methylated DNA with a DNA sample from the first source, under suitable conditions, so as to degrade methylated DNA in the first sample, and (ii) contacting an agent that degrades unmethylated DNA with a DNA sample from the second source, under suitable conditions, so as to degrade unmethylated DNA in the second sample;
  - (b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the first source and a DNA strand from the second source, should both such strands be present; and
  - (c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of differential methylation between the DNA from the first source and the corresponding DNA from the second source.
2. The method of claim 1, further comprising the step of modifying the DNA of parts (i) and (ii) resulting from step (a) with a first and second moiety, respectively, so as to prevent, in step (b), the formation of a DNA duplex consisting of DNA strands from the first source or of a DNA duplex consisting of DNA strands from the second source.

-30-

3. The method of claim 2, wherein the modification of at least one sample resulting from step (c) comprises modifying the DNA in at least one sample with a moiety which facilitates the isolation of hybrid DNA duplexes formed in step (b).
4. The method of claim 3, wherein the moiety is biotin.
5. The method of claim 1, further comprising the step of determining the nucleic acid sequence of a hybrid DNA duplex whose presence is detected in step (c).
6. The method of claim 5, further comprising the step of identifying the methylated nucleotide residues of one or both strands of the hybrid DNA duplex whose sequence is determined.
7. The method of claim 1, wherein the first and second sources of DNA are a cell from a first tissue of a subject and a cell from a second tissue of that subject, respectively.
8. The method of claim 1, wherein the first and second sources of DNA are a cell from a normal tissue and a cell from that tissue in a diseased state, respectively.
9. The method of claim 1, wherein the first and second sources of DNA are both chromosomes of a chromosome pair.
10. The method of claim 1, wherein each of the DNA samples from the first and second sources is a DNA library.
11. The method of claim 1, wherein each of the DNA samples from the first and second sources is an isolated gene.

-31-

12. The method of claim 11, wherein the isolated gene is a tumor suppressor gene.

5 13. The method of claim 1, wherein the agent that degrades methylated DNA is McrBC.

10 14. The method of claim 1, wherein the agent that degrades unmethylated DNA comprises a methylation-sensitive restriction endonuclease.

15 15. The method of claim 14, wherein the agent comprises a methylation-sensitive restriction endonuclease selected from the group consisting of HpaII, HhaI, MaeII, BstUI and AciI.

16. The method of claim 1, wherein the agent that degrades unmethylated DNA comprises a plurality of methylation-sensitive restriction endonucleases.

20 17. The method of claim 16, wherein the agent comprises a plurality of methylation-sensitive restriction endonucleases selected from the group consisting of HpaII, HhaI, MaeII, BstUI and AciI.

25 18. The method of claim 1, wherein the DNA from the first and second sources is human DNA.

30 19. A method for determining the presence of a tumor suppressor gene in a DNA sample from a tumor cell, which method comprises the steps of:

35 (a) (i) contacting an agent that degrades unmethylated DNA with the DNA sample from the tumor cell, under suitable conditions, so as to degrade unmethylated DNA in the sample, and (ii) contacting an agent that degrades methylated DNA with a DNA sample from a



-32-

normal cell corresponding to the tumor cell, under suitable conditions, so as to degrade methylated DNA in the sample;

(b) contacting the resulting samples with each other under conditions permitting reannealing between the DNA strands therein, so as to permit the formation of a hybrid DNA duplex comprising a DNA strand from the normal cell and a DNA strand from the tumor cell, should both such strands be present;

(c) detecting the formation of any such hybrid DNA duplex, such formation indicating the presence of differential methylation between the DNA from the normal cell and the corresponding DNA from the tumor cell; and

(d) determining whether the DNA strand from the tumor cell in the hybrid DNA duplex detected in step (c) comprises a tumor suppressor gene, thereby determining the presence of a tumor suppressor gene in the DNA sample from the tumor cell.

20. The method of claim 19, further comprising the step of modifying the DNA of parts (i) and (ii) resulting from step (a) with a first and second moiety, respectively, so as to prevent, in step (b), the formation of a DNA duplex consisting of DNA strands from the normal cell or of a DNA duplex consisting of DNA strands from the tumor cell.


21. The method of claim 20, wherein the modification of at least one sample resulting from step (c) comprises modifying the DNA in at least one sample with a moiety which facilitates the isolation of hybrid DNA duplexes formed in step (b).

22. The method of claim 21, wherein the moiety is biotin.

-33-

23. The method of claim 19, further comprising the step of determining the nucleic acid sequence of a hybrid DNA duplex whose presence is detected in step (c).
- 5 24. The method of claim 23, further comprising the step of identifying the methylated nucleotide residues of one or both strands of the hybrid DNA duplex whose sequence is determined.
- 10 25. The method of claim 19, wherein the agent that degrades methylated DNA is McrBC.
- 15 26. The method of claim 19, wherein the agent that degrades unmethylated DNA comprises a methylation-sensitive restriction endonuclease.
- 20 27. The method of claim 26, wherein the agent comprises a methylation-sensitive restriction endonuclease selected from the group consisting of HpaII, HhaI, MaeII, BstUI and AciI.
- 25 28. The method of claim 19, wherein the tumor cell is a human cell, and the normal cell corresponding to the tumor cell is a human cell.

1/3


**FIGURE 1**

2/3

FIGURE 2C


FIGURE 2B

FIGURE 2A



3/3

**FIGURE 3**



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US08/34159

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/16; C07H 21/04

US CL : 435/6, 198, 325; 586/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 198, 325; 586/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, DIALOG; DNA methylat+, different+, degrad+, digest+, restriction, cell, tissue, tumor suppressor

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,300,171 B1 (VULYSTEKE et al) 09 October 2001, col. 2, line 46-col. 3, line 8, claims 1-28	1-28
Y	US 6,265,171 B1 (HERMAN et al) 24 July 2001, col. 111-112, claims 1-14	1-28

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"A" document member of the same patent family

Date of the actual completion of the international search

12 DECEMBER 2002

Date of mailing of the international search report

04 FEB 2003

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 805-3230

Authorized officer

STEPHANIE ZITOMER

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)\*

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**